» Articles » PMID: 30925872

Current Patient Perspectives of Vulvovaginal Candidiasis: Incidence, Symptoms, Management and Post-treatment Outcomes

Overview
Publisher Biomed Central
Date 2019 Mar 31
PMID 30925872
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vulvovaginal candidiasis (VVC) is a common infection affecting women worldwide. Reports of patterns/risk factors/trends for episodic/recurrent VVC (RVVC) are largely outdated. The purpose of this study was to obtain current patient perspectives of several aspects of VVC/RVVC.

Methods: Business cards containing on-line survey information were distributed to healthy volunteers and patients seeking standard, elective, or referral gynecologic care in university-affiliated Obstetrics/Gynecology clinics. The internet-based questionnaire was completed by 284 non-pregnant women (78% Caucasian, 14% African American, 8% Asian).

Results: The majority of the participants (78%) indicated a history of VVC with 34% defined as having RVVC. The most common signs/symptoms experienced were itching, burning and redness with similar ranking of symptoms among VVC and RVVC patients. Among risk factors, antibiotic use ranked highest followed by intercourse, humid weather and use of feminine hygiene products. A high number of respondents noted 'no known cause' (idiopathic episodes) that was surprisingly similar among women with a history of either VVC or RVVC. VVC/RVVC episodes reported were primarily physician-diagnosed (73%) with the remainder mostly reporting self-diagnosis and treating with over-the-counter (OTC) medications. Most physician-diagnosed attacks utilized a combination of pelvic examination and laboratory tests followed by prescribed antifungals. Physician-treated cases achieved a higher level of symptom relief (84%) compared to those who self-medicated (57%). The majority of women with RVVC (71%) required continual or long-term antifungal medication as maintenance therapy to control symptoms.

Conclusions: Current patient perspectives closely reflect historically documented estimates of VVC/RVVC prevalence and trends regarding symptomatology, disease management and post-treatment outcomes.

Citing Articles

Efficacy and safety of vaginal suppositories containing combination of Natamycin and Lactulose in treatment of vulvovaginal candidiasis: international, randomized, controlled, superiority clinical trial (combination of Natamycin and Lactulose for....

Volkova O, Amelchenko E, Makeeva O, Tolmachev S, Lesovaya E, Zacharia L BMC Womens Health. 2025; 25(1):77.

PMID: 39979898 PMC: 11843759. DOI: 10.1186/s12905-025-03616-3.


Comparative efficacy of topical commercial Chinese polyherbal preparation for vulvovaginal candidiasis: a network meta-analysis.

Wu L, Jing S, Li N, Cao D, Pei F, Luo Y Front Pharmacol. 2025; 16:1484325.

PMID: 39963237 PMC: 11830678. DOI: 10.3389/fphar.2025.1484325.


Lactic acid in the vaginal milieu modulates the -host interaction.

Rosati D, Valentine M, Bruno M, Pradhan A, Dietschmann A, Jaeger M Virulence. 2025; 16(1):2451165.

PMID: 39843417 PMC: 11760238. DOI: 10.1080/21505594.2025.2451165.


Blue light-emitting diode therapy for recurrent vulvovaginal candidiasis: a Brazilian report.

Modesto W, Frederice C, Bardin M Lasers Med Sci. 2025; 40(1):21.

PMID: 39825978 DOI: 10.1007/s10103-025-04283-4.


Candida albicans migrates itself from the vagina to the uterus and ovaries in estrogenized mice.

Mosca V, Arita G, Sakita K, Rodrigues-Vendramini F, Faria D, Conrado P Braz J Microbiol. 2025; 56(1):415-423.

PMID: 39792330 PMC: 11885761. DOI: 10.1007/s42770-024-01602-9.


References
1.
Sobel J . Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992; 14 Suppl 1:S148-53. DOI: 10.1093/clinids/14.supplement_1.s148. View

2.
Fidel Jr P, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin D . An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun. 2004; 72(5):2939-46. PMC: 387876. DOI: 10.1128/IAI.72.5.2939-2946.2004. View

3.
Horowitz B, EDELSTEIN S, Lippman L . Sexual transmission of Candida. Obstet Gynecol. 1987; 69(6):883-6. View

4.
Fidel Jr P . History and new insights into host defense against vaginal candidiasis. Trends Microbiol. 2004; 12(5):220-7. DOI: 10.1016/j.tim.2004.03.006. View

5.
Achkar J, Fries B . Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010; 23(2):253-73. PMC: 2863365. DOI: 10.1128/CMR.00076-09. View